Skip Navigation

JNCI Journal of the National Cancer Institute 1991 83(4):266-273; doi:10.1093/jnci/83.4.266
© 1991 by Oxford University Press
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Weiden, P. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Weiden, P. L.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 83, No. 4, 266-273, February 20, 1991
© 1991 Oxford University Press

Preoperative Chemotherapy (Cisplatin and Fluorouracil) and Radiation Therapy in Stage III Non-Small-Cell Lung Cancer: A Phase II Study of the Lung Cancer Study Group

P. L. Weiden*, S. Piantadosi, For The Lung Cancer Study Group

Virginia Mason Clinic Seattle, Wash.
The Johns Hopkins Oncology Center Baltimore, Md.

*Correspondence to: Paul L. Weiden, MD, Virginia Mason Clinic, PO Box 900, Seattle, WA 98111

The Lung Cancer Study Group conducted a phase II pilot study of concurrent chemotherapy and radiation therapy (chemoradiotherapy) before surgery in 85 eligible patients with non-small-cell cancer limited to the chest but in whom attempted resection would have been likely to leave residual disease (advanced stage IIIA and minimal stage IIIB disease). Cisplatin, 75 mg/m2, was given on days 1 and 29; fluorouracil, 1 g/2 per 24 hours, was administered as a continuous infusion on days 1 through 4 and on days 29 through 32; and thoracic radiation, 30 Gy in 15 fractions, was administered on days 1 through 19. Two patients achieved a complete response and 46 patients had a partial response for an overall response rate of 56%. Toxicity from chemoradiotherapy was moderate but acceptable. Eight weeks after therapy was initiated, 54 patients underwent thoracotomy and tumor resection was attempted: 29 (34%) had complete resection and 15 (18%) had incomplete resection. Although surgical dissection was generally more difficult than in patients not pretreated with chemoradiotherapy, there was no apparent increase in postoperative complications. In 8 patients (9%), no viable tumor was detected pathologically in the resection specimen. Of the 18 patients whose tumors were completely resected and had disease recurrence, none had recurrence only in the chest, 12 (67%) had recurrence only in distant sites, and 3 developed second primary tumors. Median survival of all patients was 13 months. The overall results do not indicate a major benefit from this preoperative chemoradiotherapy regimen in patients with advanced but potentially resectable non-small-cell lung cancer. These results suggest a need to define better the relative roles of preoperative radiotherapy and chemotherapy. [J Natl Cancer Inst 83: 266–272, 1991]



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Clin. Cancer Res.Home page
M. M. DeCamp Jr., S. Ashiku, and R. Thurer
The Role of Surgery in N2 Non-Small Cell Lung Cancer
Clin. Cancer Res., July 1, 2005; 11(13): 5033s - 5037s.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
D. Farray, N. Mirkovic, and K. S. Albain
Multimodality Therapy for Stage III Non-Small-Cell Lung Cancer
J. Clin. Oncol., May 10, 2005; 23(14): 3257 - 3269.
[Abstract] [Full Text] [PDF]


Home page
Ann OncolHome page
G. P. Stathopoulos, M. Veslemes, N. Georgatou, D. Antoniou, P. Giamboudakis, K. Katis, D. Tsavdaridis, S. K. Rigatos, I. Dimitroulis, S. Bastani, et al.
Front-line paclitaxel-vinorelbine versus paclitaxel-carboplatin in patients with advanced non-small-cell lung cancer: a randomized phase III trial
Ann. Onc., July 1, 2004; 15(7): 1048 - 1055.
[Abstract] [Full Text] [PDF]


Home page
Ann OncolHome page
L. Trodella, P. Granone, S. Valente, S. Margaritora, G. Macis, A. Cesario, R. M. D'Angelillo, V. Valentini, G. M. Corbo, V. Porziella, et al.
Neoadjuvant concurrent radiochemotherapy in locally advanced (IIIA-IIIB) non-small-cell lung cancer: long-term results according to downstaging
Ann. Onc., March 1, 2004; 15(3): 389 - 398.
[Abstract] [Full Text] [PDF]


Home page
Ann. Thorac. Surg.Home page
D. Galetta, A. Cesario, S. Margaritora, V. Porziella, G. Macis, R. M. D'Angelillo, L. Trodella, S. Sterzi, and P. Granone
Enduring challenge in the treatment of nonsmall cell lung cancer with clinical stage IIIB: results of a trimodality approach
Ann. Thorac. Surg., December 1, 2003; 76(6): 1802 - 1809.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Crit. Care Med.Home page
S. G. Spiro and J. C. Porter
Lung Cancer--Where Are We Today?: Current Advances in Staging and Nonsurgical Treatment
Am. J. Respir. Crit. Care Med., November 1, 2002; 166(9): 1166 - 1196.
[Abstract] [Full Text] [PDF]


Home page
Ann. Thorac. Surg.Home page
A. Cyjon, M. Nili, G. Fink, M. R. Kramer, E. Fenig, J. Sandbank, A. Sulkes, and E. Rakowsky
Advanced non-small cell lung cancer: induction chemotherapy and chemoradiation before operation
Ann. Thorac. Surg., August 1, 2002; 74(2): 342 - 347.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
J. Martin, R. J. Ginsberg, E. S. Venkatraman, M. S. Bains, R. J. Downey, R. J. Korst, M. G. Kris, and V. W. Rusch
Long-Term Results of Combined-Modality Therapy in Resectable Non-Small-Cell Lung Cancer
J. Clin. Oncol., April 15, 2002; 20(8): 1989 - 1995.
[Abstract] [Full Text] [PDF]


Home page
Ann OncolHome page
C. Pottgen, W. Eberhardt, S. Bildat, G. Stuben, G. Stamatis, L. Hillejan, S. Sohrab, H. Teschler, S. Seeber, H. Sack, et al.
Induction chemotherapy followed by concurrent chemotherapy and definitive high-dose radiotherapy for patients with locally advanced non-small-cell lung cancer (stages IIIa/IIIb): a pilot phase I/II trial
Ann. Onc., March 1, 2002; 13(3): 403 - 411.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
L. Trodella, P. Granone, S. Valente, A. Turriziani, G. Macis, G. M. Corbo, S. Margaritora, A. Cesario, R. M. D'Angelillo, G. Gualano, et al.
Phase I Trial of Weekly Gemcitabine and Concurrent Radiotherapy in Patients With Inoperable Non-Small-Cell Lung Cancer
J. Clin. Oncol., February 1, 2002; 20(3): 804 - 810.
[Abstract] [Full Text] [PDF]


Home page
ChestHome page
K. Junker, K. Langner, F. Klinke, U. Bosse, and M. Thomas
Grading of Tumor Regression in Non-small Cell Lung Cancer : Morphology and Prognosis
Chest, November 1, 2001; 120(5): 1584 - 1591.
[Abstract] [Full Text] [PDF]


Home page
ChestHome page
G. M. Strauss
Role of Chemotherapy in Stages I to III Non-small Cell Lung Cancer*
Chest, December 1, 1999; 116 (2009): 509S - 516S.
[Abstract] [Full Text] [PDF]


Home page
Ann. Thorac. Surg.Home page
G. Stamatis, W. Eberhardt, G. Stuben, S. Bildat, O. Dahler, and L. Hillejan
Preoperative chemoradiotherapy and surgery for selected non-small cell lung cancer IIIB subgroups: long-term results
Ann. Thorac. Surg., October 1, 1999; 68(4): 1144 - 1149.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
M. Stuschke, W. Eberhardt, C. Pottgen, G. Stamatis, H. Wilke, G. Stuben, F. Stoblen, H. H. Wilhelm, H. Menker, H. Teschler, et al.
Prophylactic Cranial Irradiation in Locally Advanced Non-Small-Cell Lung Cancer After Multimodality Treatment: Long-Term Follow-Up and Investigations of Late Neuropsychologic Effects
J. Clin. Oncol., September 1, 1999; 17(9): 2700 - 2700.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
M. Thomas, C. Rube, M. Semik, M. von Eiff, L. Freitag, H. N. Macha, W. Wagner, F. Klinke, H. H. Scheld, N. Willich, et al.
Impact of Preoperative Bimodality Induction Including Twice-Daily Radiation on Tumor Regression and Survival in Stage III Non-Small-Cell Lung Cancer
J. Clin. Oncol., April 1, 1999; 17(4): 1185 - 1185.
[Abstract] [Full Text] [PDF]


Home page
Eur. J. Cardiothorac. Surg.Home page
J. Vansteenkiste, P. De Leyn, G. Deneffe, J. Menten, T. Lerut, and M. Demedts
Present status of induction treatment in stage IIIA-N2 non-small cell lung cancer: a review
Eur. J. Cardiothorac. Surg., January 1, 1998; 13(1): 1 - 12.
[Abstract] [Full Text] [PDF]


Home page
J. Thorac. Cardiovasc. Surg.Home page
D. J. Sugarbaker, J. Herndon, L. J. Kohman, M. J. Krasna, M. R. Green, t. C. a. L. G. B T. S. Group, and S. b. V. Rusch
Results of cancer and leukemia group B protocol 8935A multiinstitutional phase II trimodality trial for stage IIIa (N2) non-small-cell lung cancer
J. Thorac. Cardiovasc. Surg., March 1, 1995; 109(3): 473 - 485.
[Abstract] [Full Text]


Home page
NEJMHome page
R. Rosell, J. Gomez-Codina, C. Camps, J. Maestre, J. Padille, A. Canto, J. L. Mate, S. Li, J. Roig, A. Olazabal, et al.
A Randomized Trial Comparing Preoperative Chemotherapy Plus Surgery with Surgery Alone in Patients with Non-Small-Cell Lung Cancer
N. Engl. J. Med., January 20, 1994; 330(3): 153 - 158.
[Abstract] [Full Text]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.